Drug-Induced Mitochondrial Dysfunction (PDF)

Contributors. Preface. Part I: Basic Concepts. 1. Basic Mitochondrial Physiology in Cell Viability and Death (Lech Wojtczak and Krzysztof Zabtocki). 2. Basic Molecular Biology of Mitochondrial Replication (Immo E. Scheffler). 3. Drug-Associated Mitochondrial Toxicity (Rhea Mehta, Katie Chan, Owen Lee, Shahrzad Tafazoli, and Peter J. O'Brien). 4. Pharmacogenetics of Mitochondrial Drug Toxicity (Neil Howell and Corinna Howell). Part II: Organ Drug Toxicity: Mitochondrial Etiology. 5. Features and Mechanisms of Drug-Induced Liver Injury (Dominique Pessayre, Alain Berson, and Bernard Fromenty). 6. Cardiovascular Toxicity of Mitochondrial Origin (Paulo J. Oliveira, Vilma A. Saradao, and Kendall B. Wallace). 7. Skeletal Muscle and Mitochondrial toxicity (Timothy E. Johnson). 8. Manifestations of Drug Toxicity on Mitochondria in the Nervous System (Ian J. Reynolds). 9. Lipoatrophy and Other Manifestations of Antiretroviral Therapeutics (Ulrich A. Walker). 10. Nephrotoxocity (Alberto Ortiz, Alberto Tejedor, and Carlos Caramelo). 11. Drug Effects in Patients with Mitochondrial Diseases (Eric A. Schon, Michio Hirano, and Salvatore DiMauro). Part III: Assessment of Mitochondrial Function in Vitro and In Vivo. 12. Polarographic Oxygen Sensors, the Oxygraph, and High-Resolution Respirometry to Assess Mitochondrial Function (Erich Gnaiger). 13. Use of Oxygen-Sensitive Fluorescent Probes for the Assesment of Mitochondrial Function (James Hynes, Tomas C. O'riordan, and Dmitri B. Papkovsky). 14. Mitochondrial Dysfunction Assessed Quantitatively in Real Time by Measuring the Extracellular Flux of Oxygen and Protons (David Ferrick, Min Wu, Amy Swift, and Andy Neilson). 15. Assessment of Mitochondrial Respiratory Complex Function In Vitro and In Vivo (Mark A. Birch -Machin). 16. OXPHOS Complex Activity Assays and Dipstick Immunoassays for Assessment of OXPHOS Protein Levels (Sashi Nadanaciva). 17. Use of Fluorescent Reporters to Measure Mitochondrial Membrane Potential and the

James A. Dykens, PhD, is an Associate Research Fellow in
Pfizer's Drug Safety Research and Development Department. Currently
in Sandwich, England, he previously worked in a similar role with
Pfizer in La Jolla, California. Prior to his work with Pfizer, Dr.
Dykens was the senior director of technology development for
MIGENIX Inc., a senior scientist and the director of business
development at MitoKor, Inc., and a senior principal scientist at
Parke-Davis Pharmaceutical Research. Dr. Dykens has published
extensively on drug-induced mitochondrial dysfunction, on the role
of mitochondrial free radical production in the etiology of
neurodegenerative diseases, and on the physiological ecology of
marine symbioses.

Yvonne Will, PhD, works in Pfizer's Exploratory Safety
Differentiation Group in Groton, Connecticut. Prior to this
position, she led Pfizer's Investigative Biochemical Toxicity Group
within the Drug Safety Research and Development Department in La
Jolla. Before joining Pfizer, Dr. Will worked on mitochondrial
proteomics and physiology at MitoKor, Inc. Dr. Will has authored a
host of articles and book chapters. She is a member of the Society
of Toxicology and a frequent speaker for groups like ACT and World
Pharmaceutical Congress.

Dieses eBook können Sie uneingeschränkt auf allen Geräten der tolino Familie lesen. Zum Lesen auf sonstigen eReadern und am PC benötigen Sie eine Adobe ID.